Stockreport

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

Geron Corporation  (GERN) 
Last geron corporation earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: geron.com/investors
PDF Analyses pooling data from IMerge Phase 2, Phase 3 and the QTc substudy suggest patients who were ESA ineligible or who had prior treatment with luspatercept or lenalido [Read more]